The Waiting Room
In June 2021, a company that most Americans had never heard of — and that most doctors had been using for years — went public at $26 a share on the New York Stock Exchange, priced modestly by the standards of a tech market drunk on its own momentum. By market close, Doximity's stock had surged 104%, valuing the company at roughly $10 billion. The firm had 1.8 million verified physician members in the United States, which is to say: more than 80% of every doctor in the country. It employed fewer than 800 people. Its EBITDA margins exceeded 50%. The business had been profitable for years before the IPO, a detail so unusual among venture-backed health-tech companies that it bordered on the suspicious. Here was a social network for physicians — a LinkedIn for doctors, the shorthand went, though the comparison obscured more than it revealed — that had quietly become the dominant professional platform in one of the most difficult verticals in technology, built with a capital efficiency that would have embarrassed most SaaS companies a fraction of its size. The question the market was really asking, behind the frothy first-day pop, was simpler and stranger: How had something this profitable stayed this invisible for this long?
The answer begins with the man who built it and the peculiar insight that animated the company from its earliest days — that physicians, despite being among the most economically powerful professionals in America, were also among the most technologically underserved.
By the Numbers
Doximity at a Glance
80%+U.S. physicians on the platform
~2MVerified medical professional members
$529MRevenue (FY2025 ending March 2025)
~53%Adjusted EBITDA margin
$186M+Net income (FY2024)
~800Employees
$8B+Market capitalization (mid-2025)
The Doctor's Rolodex
Jeff Tangney grew up in a military family, moving every few years, the kind of childhood that teaches you to read new rooms quickly. He studied electrical engineering at Stanford, then earned an MBA there too — the classic Silicon Valley double-helix credential — but his career took an unusual detour through healthcare. Before Doximity, Tangney co-founded Epocrates, one of the first successful mobile apps for physicians, a drug-reference tool that at its peak was installed on the phones of more than half of all U.S. doctors. Epocrates proved something important: doctors would adopt technology, enthusiastically even, if it respected the texture of their actual workflow rather than imposing the logic of consumer tech. It also proved something Tangney found even more interesting — pharmaceutical companies would pay handsomely to reach doctors through digital channels, if the audience was verified and the context was professional.
But Epocrates was a point solution. A drug-reference app. Tangney's bigger observation, which would become the founding thesis of Doximity in 2010, was that the connective tissue of American medicine — how doctors found each other, referred patients, communicated about cases, stayed current with research, navigated their own careers — was astonishingly primitive. The average physician in 2010 was still faxing referral letters. Credentialing for hospital privileges involved mailing notarized documents. If a cardiologist in Houston wanted to consult with a neurologist at Mass General about a shared patient, the most common pathway was a phone call through an operator, a pager, or nothing at all. The informal professional network that doctors relied on — who's good, who's available, who's taking new patients — lived almost entirely inside individual heads and Rolodexes.
Tangney saw this gap not as a consumer social problem but as an infrastructure problem. The social layer was a means, not the end. If you could build a verified, comprehensive directory of every physician in America — their specialties, affiliations, training, publications, even their referral patterns — and then layer communication tools, news, and career services on top, you would create something closer to a professional operating system than a social network. And crucially, you would control the most valuable audience in healthcare marketing: the physicians who write prescriptions, order procedures, and direct the flow of trillions of dollars in healthcare spending.
We're not trying to be Facebook for doctors. We're trying to be the professional platform where medicine gets done.
The Verification Moat
The decision that made everything else possible was also the decision that made Doximity excruciatingly slow to build in its early years: physician verification.
From day one, Tangney insisted that every member on the platform be a verified medical professional. Not a patient, not a curious consumer, not a medical student (though they were later added), but a licensed physician or advanced practice provider whose credentials had been independently confirmed. This was not a checkbox. Doximity built an identity-verification engine that cross-referenced DEA numbers, state medical licenses, NPI numbers, medical school records, and residency affiliations. The process was rigorous enough that the platform would later be accepted by the federal government for EPCS — Electronic Prescribing of Controlled Substances — a regulatory designation that requires a level of identity assurance well beyond what any social network had ever attempted.
The implications of this decision cascaded through the entire business model. A verified physician network meant that every interaction on the platform — every message, every referral, every article read, every job listing viewed — carried implicit professional credentialing. It meant pharmaceutical companies could target their marketing with a precision impossible through any other digital channel, because the audience wasn't probabilistic; it was deterministic. When Pfizer bought an ad campaign on Doximity, it wasn't hoping the ad reached cardiologists. It knew. And it meant that physicians themselves trusted the platform in a way they never trusted LinkedIn or Facebook, because the verification wall kept out the noise — the recruiters, the patients, the wellness influencers, the supplement hucksters.
This trust became the company's central asset. In an industry defined by information asymmetry, regulatory complexity, and professional gatekeeping, trust is not a feature. It's the architecture.
But the cost was real. Verification at this scale required a sustained investment in data infrastructure that generated no immediate revenue. Doximity spent its early years building the most comprehensive physician database in the country — a proprietary asset that now covers essentially every practicing physician in America, including many who aren't active members of the platform. The company compiled data from public sources, licensing boards, hospital systems, and medical associations, then layered its own behavioral data on top: which physicians read which articles, which ones are actively seeking new positions, which referral networks are densest in which metropolitan areas.
By the time competitors recognized what Doximity was building, the verification moat was essentially unassailable. You cannot build a verified network of 80% of American physicians from scratch. The network already exists. It is called Doximity.
The Attention Bottleneck
The pharmaceutical industry in the United States spends approximately $30 billion per year marketing to physicians — a figure that has remained remarkably stable even as the channels have shifted. For decades, this spending was dominated by the pharmaceutical sales representative, the detail rep, the person in the well-cut suit carrying a briefcase of samples into a doctor's office. At the peak, the industry employed more than 100,000 reps in the U.S. alone.
That model has been dying for twenty years. Physicians increasingly refuse to see reps. Hospital systems restrict access. The COVID-19 pandemic accelerated the decline by making in-person visits impossible for months. By 2023, the number of pharma reps in the U.S. had fallen below 50,000 and continued to shrink. But the marketing budgets didn't shrink with them. They went looking for new channels.
Doximity was waiting.
The company's commercial model is deceptively simple. Pharmaceutical companies and health systems pay Doximity to reach physicians through the platform — via targeted content, sponsored articles, interactive modules, and increasingly sophisticated digital engagement tools. The product isn't a banner ad. It's a native content experience that resembles an article in a medical journal more than it resembles a display campaign. Physicians engage because the content is professionally relevant. Pharma companies pay because the targeting is precise and the engagement is measurable. Doximity takes a cut of a $30 billion annual budget that has been shifting from feet-on-the-street to digital for two decades and is still only about 15–20% digitized.
This is the bull case in a sentence: Doximity owns the dominant platform for the largest underdigitized professional marketing budget in the American economy.
In pharma marketing, the shift to digital has been talked about for fifteen years. It's actually happening now, and there aren't that many places for the money to go.
The revenue model concentrates around what Doximity calls its "marketing solutions" offering — essentially a media business where the inventory is physician attention and the buyers are pharmaceutical companies, biotech firms, medical device manufacturers, and health systems. This segment generates the vast majority of revenue and operates at software-like margins because the marginal cost of serving an additional ad impression to a physician who's already on the platform is effectively zero.
The company supplements this with a hiring solutions business — a job board and recruitment platform for physicians — and a growing telehealth offering. But these are secondary. The engine is pharma marketing, and the fuel is physician engagement.
COVID's Amplifier
If Doximity's pre-pandemic trajectory was a steady upward line, COVID-19 bent it into an exponential curve. The pandemic transformed the company's fortunes in three distinct ways, each compounding the others.
First, physician engagement on the platform surged. Doctors were isolated, anxious, and desperate for real-time clinical information. Doximity became one of the primary channels through which physicians shared early treatment protocols, case reports, and evolving guidance on a novel virus. The platform's news feed, which aggregates medical literature and peer commentary, saw usage spikes that would have taken years to achieve organically.
Second, telehealth went from a regulatory curiosity to an overnight necessity. Doximity had launched a video-calling tool called Dialer in 2019 — a telehealth feature designed specifically for physicians, with the critical advantage that it used the doctor's office phone number as the caller ID, preserving patient trust and professional boundaries. When the pandemic hit, Dialer usage exploded. By 2021, Doximity claimed that its telehealth tools facilitated more patient visits than any other platform, including dedicated telehealth companies like Teladoc and Amwell. The tool was free for physicians — a deliberate strategic choice — which meant it was adopted friction-free by tens of thousands of doctors who had never used telehealth before.
Third, and most consequentially for the business model, pharmaceutical marketing budgets that had been allocated to in-person rep visits had nowhere to go. Reps couldn't visit offices. Conferences were cancelled. Medical education events went virtual. The marketing dollars flooded into digital channels, and Doximity — with its verified audience, its engagement data, and its native content formats — captured a disproportionate share.
📈
COVID-Era Revenue Acceleration
Doximity's fiscal year ends March 31
FY2020Revenue: $116.4M. Pre-pandemic baseline.
FY2021Revenue: $206.9M. 78% YoY growth. Pandemic engagement surge.
FY2022Revenue: $343.5M. 66% YoY growth. Pharma digital budgets accelerate.
FY2023Revenue: $419.2M. 22% YoY growth. Normalization begins.
FY2024Revenue: $470.5M. 12% YoY growth. Post-COVID deceleration.
FY2025Revenue: $529.0M (est). ~12% YoY growth. Stabilization at scale.
The COVID windfall was real — but so was the hangover. As the pandemic receded, some of the engagement spike normalized. Pharma companies recalibrated their digital-versus-physical spending mix. Growth decelerated from the dizzying 60–80% range into the low teens, and the stock, which had peaked above $100 in late 2021, gave back most of its gains through 2022 and 2023. The question the market has been debating ever since is whether the pre-pandemic trajectory or the pandemic peak better represents the company's true growth rate — and whether the secular shift to digital pharma marketing is large enough and fast enough to reignite revenue acceleration.
The Unusual Economics of a Shadow Monopoly
Doximity's financial profile is among the most unusual in enterprise software, healthcare technology, or media — the three categories it loosely straddles. Consider the numbers: roughly $500 million in revenue, adjusted EBITDA margins consistently above 50%, net income margins above 35%, and free cash flow generation so strong that the company has been buying back stock aggressively since going public. The employee base has stayed remarkably lean — roughly 800 people generating revenue per employee north of $600,000, a figure that approaches the efficiency of Veeva Systems, the other healthcare software company that has built a category-defining franchise with unusual discipline.
The margin structure reflects something fundamental about the business model. Doximity's costs are overwhelmingly fixed. The platform's engineering, data science, content curation, and verification infrastructure cost roughly the same whether 100 pharmaceutical companies or 200 are buying campaigns. Every incremental dollar of revenue drops to the bottom line with minimal marginal cost. This is the operating leverage profile of a platform business with a captive audience, not a services business that scales linearly with headcount.
But the margins also reflect a choice. Tangney has been conspicuously disciplined about not chasing revenue lines that would dilute profitability. The company has not built a large sales force — its go-to-market is concentrated on a relatively small number of enterprise pharmaceutical accounts, each of which represents a large contract. It has not expanded aggressively into adjacent verticals. It has not acquired companies at inflated multiples to buy growth. The entire culture of the company — remote-first since before it was fashionable, headquartered in San Francisco but operationally distributed, with a management team that talks more about free cash flow per share than top-line growth — reflects a founder who is optimizing for something closer to compounding value per share than for hitting an arbitrary revenue target.
We're a team of under 800 people, and we intend to stay lean. We've seen too many companies get bloated during the good times and then have to restructure during the bad times. We'd rather just stay lean all the time.
The comparison to Veeva is instructive and possibly flattering. Both companies identified a specific, underserved vertical within healthcare (Veeva: life sciences
CRM and regulatory; Doximity: physician professional networking and pharma marketing). Both built dominant market positions with remarkable capital efficiency. Both enjoy revenue concentration risk that doubles as a moat — their customers are pharmaceutical companies with enormous budgets and slow procurement cycles, making the revenue base sticky but concentrated. And both have founders who remained CEO for extended periods, maintaining strategic coherence over growth-at-all-costs pressure.
The difference is that Veeva's products are deeply embedded in its customers' operational workflows — clinical trials, regulatory submissions, commercial operations — while Doximity's value proposition is more akin to a media company selling access to an audience. This distinction matters enormously when you think about durability. Veeva's switching costs are operational. Doximity's switching costs are attention-based. One is anchored in enterprise IT budgets. The other is anchored in marketing budgets. And marketing budgets, for all their stickiness in aggregate, are far more discretionary at the firm level.
The Twenty Largest Pharma Companies in the World
Doximity discloses a metric it calls "net revenue retention rate" — the percentage of revenue from existing customers that it retains and grows year-over-year. This number has consistently been above 110%, meaning existing customers spend more each year. But the figure obscures a concentration dynamic that is both the company's greatest strength and its most vulnerable flank.
The top twenty pharmaceutical companies in the world account for a disproportionate share of Doximity's revenue. The company has disclosed that its top twenty customers typically represent 50–60% of total revenue. This is not unusual for an enterprise-focused business, but it creates a specific kind of risk: a single large customer pulling back — because of a patent cliff, a product launch delay, a regulatory setback, or simply a change in marketing philosophy — can move the needle on quarterly results.
The pharma industry is structurally cyclical in a way that tech investors sometimes underappreciate. A pharmaceutical company's marketing spending is tightly correlated with its drug launch calendar. When a blockbuster drug is approaching launch, the company spends aggressively on physician awareness campaigns — and Doximity benefits. When the drug goes generic, or when a clinical trial fails and the pipeline thins, spending contracts. This creates a lumpy, somewhat unpredictable revenue cadence that is fundamentally different from the predictable seat-based expansion of classic SaaS.
Doximity has tried to smooth this cyclicality by expanding the number of pharmaceutical modules it offers — interactive content formats, medical education programs, speaking engagement tools — and by growing its base of smaller biotech and medical device customers. But the gravitational pull of Big Pharma budgets is inescapable. The company's growth is downstream of pharmaceutical R&D productivity, which is downstream of FDA approval cadences, which are downstream of the stochastic process of drug discovery. This is not a criticism. It is a structural fact about the market Doximity has chosen to dominate.
The Telehealth Gambit
Doximity's telehealth tools are free for physicians. This fact is repeated so often in company presentations that it begins to sound like a marketing slogan, but it is actually one of the most strategically consequential decisions the company has made — and one of the least understood.
The telehealth market post-COVID has been brutal for pure-play companies. Teladoc, which paid $18.5 billion for Livongo at the peak of pandemic enthusiasm, wrote down $13.4 billion of that investment in 2022. Amwell's stock has fallen more than 90% from its highs. The promise of telehealth as a standalone business — replacing physical visits with virtual ones at scale — has collided with the reality that most healthcare is stubbornly physical, that reimbursement rates for virtual visits remain lower than in-person, and that patient and physician behavior has partially reverted to pre-pandemic norms.
Doximity sidestepped this entire mess by never trying to monetize telehealth directly. Its Dialer tool is free because it serves a different purpose: engagement. Every time a physician uses Doximity's telehealth tools to call a patient, that physician is on the platform. That session generates behavioral data. That data makes the physician's profile richer, which makes the platform more valuable to pharmaceutical marketers, which is where the money actually is.
This is the complement-pricing strategy in its purest form. Give away the complement (telehealth) to strengthen the core product (the physician engagement platform that pharma pays to access). The telehealth tools are not a business. They are a feature designed to increase the time physicians spend inside Doximity's ecosystem, which directly improves the metrics — engagement, session frequency, data richness — that pharmaceutical companies use to evaluate their marketing spend.
It is a brilliant maneuver, but it carries a risk: the company is structurally undermonetizing an asset. If a competitor built a better physician telehealth tool and bundled it with a meaningful physician network, the engagement moat that Doximity's free telehealth creates could be replicated. So far, no one has done this. The barriers are significant — you'd need the verified physician directory, the messaging infrastructure, and the telehealth tool, all wrapped in a platform physicians actually trust. But the risk is worth naming because it is the kind of risk that is invisible right up until the moment it materializes.
The AI Bet
In 2023, as the rest of the technology industry was scrambling to append "AI" to every product description, Doximity quietly launched a set of features that were both less flashy and more immediately practical than most AI announcements in healthcare.
The company introduced AI-powered tools for clinical documentation — assisting physicians in generating after-visit summaries, patient communications, and prior authorization letters. The positioning was deliberate: these were not diagnostic tools, not clinical decision support, not anything that touched the practice of medicine itself. They were administrative tools designed to reduce the paperwork burden that surveys consistently identify as the primary driver of physician burnout.
This is a subtle but important distinction. The regulatory and liability landscape for AI in clinical decision-making is a minefield — the FDA is still working out frameworks, malpractice implications are uncharted, and physician adoption of AI-generated diagnoses is, understandably, cautious. But administrative AI? The physician who spends two hours every evening writing chart notes doesn't need FDA clearance to use a tool that drafts a letter to an insurance company. The risk profile is fundamentally different, and the user demand is immediate.
Doximity's advantage here is its dataset. With more than a decade of physician communication patterns, millions of faxed referral letters digitized, and the behavioral data generated by 2 million medical professionals using the platform, the company has a training corpus for healthcare-specific language models that would be extraordinarily difficult to replicate. Whether this becomes a meaningful revenue driver — through premium subscriptions, enterprise licensing to health systems, or enhanced marketing analytics — remains to be seen. But the strategic logic is sound: use AI to deepen engagement (more time on platform, more problems solved, more data generated) which in turn strengthens the core advertising business.
Doctors don't need another AI tool making clinical decisions. They need an AI tool that handles the three hours of paperwork they do after the clinic closes.
The Culture of the Small Team
Doximity has resisted the growth-era imperative to scale headcount as aggressively as revenue. This is not accidental, and it is not simply about protecting margins — though it does that. It reflects a philosophical commitment from Tangney that the best technology companies maintain a ratio of builders to operators that skews heavily toward builders.
The company was remote-first before the pandemic made it fashionable, with employees distributed across the country. There is no sprawling campus, no in-house chef program, no corporate shuttle. The culture reads more like a bootstrapped startup that happened to go public than a venture-backed platform that IPO'd at $10 billion. Equity ownership is concentrated among long-tenured employees, with Tangney himself maintaining a significant stake that aligns his incentives with long-term shareholders.
This leanness creates organizational speed. The company ships product updates, runs marketing experiments, and responds to physician feedback with a velocity that belies its public-company status. But it also creates brittleness. With fewer than 800 employees supporting a platform used by 2 million physicians, the margin for error in hiring is razor-thin. Losing a handful of key engineers or data scientists would be felt across the entire organization.
The capital allocation philosophy is equally disciplined. Doximity has not made a single major acquisition since its founding — a remarkable fact for a company that has been sitting on hundreds of millions in cash. Instead, it has directed excess cash flow almost entirely toward share repurchases. Since the IPO, the company has bought back well over $1 billion of its own stock, reducing its share count meaningfully. This is Tangney's explicit bet: the best use of Doximity's cash is Doximity's shares, because the business is compounding at rates that are difficult to replicate through M&A.
Whether this is brilliant capital allocation or missed opportunity depends entirely on what you think the company's reinvestment runway looks like. If Doximity can sustain low-teens revenue growth with 50%+ margins indefinitely, the buyback strategy is almost certainly the right call — it compounds per-share value in a way that avoids the integration risk of acquisitions. If the market eventually demands faster growth, the absence of adjacent businesses built through M&A will look like a strategic gap.
What LinkedIn Isn't
The "LinkedIn for doctors" comparison is irresistible and mostly wrong. It captures the surface-level similarity — both are professional networks organized around verified career identities — but misses the structural differences that explain why Doximity has succeeded where LinkedIn has failed to penetrate healthcare meaningfully.
LinkedIn is a horizontal platform. It serves every profession, which means it serves no profession deeply. A physician's LinkedIn profile looks identical in structure to a marketing manager's. The content feed is generic. The messaging system is clogged with recruiter spam. There is no mechanism for HIPAA-compliant communication, no verified credential layer, no integration with the regulatory infrastructure of medical practice.
Doximity is a vertical platform. Everything about it is designed for the specific workflows, regulatory constraints, and professional norms of medicine. The verification layer ensures that when a surgeon sends a message about a patient case, the recipient is a verified physician — not a random connection. The news feed surfaces peer-reviewed medical literature, not thought leadership posts. The career tools reflect the specific credentialing requirements of medical hiring — privileges, board certifications, malpractice history — that general-purpose job boards cannot accommodate.
This vertical depth is what creates the engagement that pharma companies are willing to pay for. A physician who spends time on Doximity is in a professional context. Their attention is focused, their identity is verified, and their engagement signals are meaningful. This is qualitatively different from the same physician scrolling LinkedIn between patients, and it commands a qualitatively different CPM.
The deeper distinction is about the business model. LinkedIn monetizes through three channels: hiring solutions, advertising, and premium subscriptions. Doximity monetizes primarily through pharmaceutical marketing — a channel that doesn't exist on LinkedIn because LinkedIn lacks the verified physician audience that makes pharmaceutical targeting valuable. The two platforms are not really competing. They serve different layers of a physician's professional life.
Microsoft, which owns LinkedIn, has periodically been discussed as a potential acquirer of Doximity. The logic would be straightforward: bolt Doximity's vertical physician network onto LinkedIn's horizontal platform and Microsoft's healthcare cloud ambitions. So far, this has remained speculation, and Doximity's market cap — fluctuating between $6 billion and $12 billion depending on the quarter — would make it a large but not impossible acquisition. Tangney's significant ownership stake and the company's strong independent financial performance suggest he is not eager to sell.
The Revenue per Physician
There is a simple way to think about Doximity's growth potential that cuts through the noise of quarterly guidance and pharma budget cycles. The company has roughly 2 million medical professional members. It generates roughly $500 million in revenue. That implies roughly $250 in annual revenue per member — a number that, when compared to the value a single physician represents to the healthcare economy, looks almost absurdly low.
The average U.S. physician generates between $2 million and $3 million in annual healthcare revenue through their prescribing decisions, procedure orders, and referral patterns. Pharmaceutical companies, in aggregate, spend approximately $15,000 per physician per year on marketing. Doximity captures roughly $250 per physician per year. Even if you argue that not all physicians on the platform are actively engaged (Doximity discloses that roughly 500,000 are "unique active users" in a given quarter), the revenue per active physician is still roughly $1,000 — a fraction of the per-physician marketing spend.
The bull case is that Doximity has enormous room to grow revenue per physician without adding a single new member. By expanding the types of marketing modules it offers, increasing the number of pharma customers, layering on AI-driven analytics products, and monetizing its hiring and telehealth features, the company could double or triple its revenue per physician over the next decade without exhausting the addressable budget.
The bear case is that pharma marketing budgets are not infinitely elastic, that the shift from in-person to digital is not linear, and that at some point, Doximity's pricing power will be constrained by the willingness of pharma companies to keep increasing their digital marketing spend — a spend that, unlike enterprise software licenses, does not produce easily quantifiable ROI metrics.
Both cases are probably partially right. The truth, as usual, lives in the gradient.
A Fax Machine in a Data Center
There is an image that captures the paradox of Doximity better than any financial metric. Somewhere in the company's infrastructure — literal or virtual — there is a system that processes faxes. Millions of them. In 2024. Because American healthcare still runs on fax machines, and Doximity, in building the connective tissue of physician communication, had to meet the system where it was.
The company's e-fax service is one of its most-used features and one of its least-discussed. Physicians use it to send referral letters, receive prior authorization documents, and communicate with other providers who haven't yet migrated to electronic systems. It is unglamorous. It is essential. And it is a perfect metaphor for the company's broader strategy: don't try to revolutionize healthcare workflows from the top down. Digitize them, gradually, from the inside. Earn trust by solving the most mundane problems first — the fax that needs sending, the credential that needs verifying, the article that needs reading at 11 p.m. after the kids are asleep — and then, once you are embedded in the daily rhythm of a physician's professional life, use that position to introduce more sophisticated tools.
The fax machine is also a moat. Every fax sent through Doximity is a data point. Every referral letter digitized is a node in a network graph of physician relationships. Every prior authorization processed is a signal about drug usage patterns, insurer behavior, and patient flow. This mundane, operational data — the exhaust of daily medical practice — is the raw material for the AI models, the marketing analytics, and the engagement algorithms that make the platform valuable to its paying customers.
Doximity, in the end, is a company that built a $500 million revenue business on the insight that the most powerful professionals in America were still using a 1960s communication device — and that whoever replaced that device, gently and without disruption, would earn the right to build the platform that sits between pharmaceutical companies and the physicians who prescribe their drugs. Jeff Tangney bet, in 2010, that the fax machine was the door. Fifteen years later, with 80% of American doctors on his platform and margins that would make a SaaS founder weep, the bet has paid. But the building is not finished. The physician's entire professional operating system — communication, credentialing, education, career management, clinical workflow — remains partially digitized, partially analog, partially fax. And Doximity, lean, profitable, and patient, is still processing the faxes.
What follows are the operating principles embedded in Doximity's strategy and execution — not merely what the company says it does, but what its actions, capital allocation, and market position reveal about how it actually operates. These principles are drawn from the evidence of Part I and distilled into tactical frameworks for founders and operators building in complex, regulated, or vertical markets.
Table of Contents
- 1.Verify first, monetize second.
- 2.Give away the complement to own the core.
- 3.Meet the market where it faxes.
- 4.Build for the buyer, not the user — then make the user love you anyway.
- 5.Stay small to stay fast.
- 6.Let concentration be your moat, not your vulnerability.
- 7.Compound per share, not per headline.
- 8.Own the vertical stack, not the horizontal layer.
- 9.Turn mundane data exhaust into strategic intelligence.
- 10.Time your expansion to trust, not ambition.
Principle 1
Verify first, monetize second.
Doximity spent its earliest years building a verification infrastructure that generated no revenue. The decision to confirm every physician's identity — cross-referencing DEA numbers, NPI databases, state licensing boards, and medical school records — was expensive, slow, and invisible to the end user who simply experienced a sign-up flow. But it was the foundation for everything that followed. The verification layer is what makes pharmaceutical companies trust that their marketing spend is reaching real physicians, not bots or medical students. It is what makes the platform acceptable for EPCS-compliant electronic prescribing. It is what makes physicians trust the platform enough to discuss real cases.
The lesson extends well beyond healthcare. In any market where the identity and credential of the user is the product's core value proposition — professional services, financial services, regulated industries — the instinct to skip verification in favor of faster user acquisition is almost always wrong. Verification is a front-loaded cost that creates compounding returns.
Benefit: A verified user base is exponentially more valuable to enterprise buyers than an unverified one. It creates a quality signal that cannot be faked and switching costs that cannot be replicated easily.
Tradeoff: Verification throttles growth. Doximity's user acquisition in the early years was painfully slow compared to consumer social networks. The company had to resist internal and external pressure to loosen standards for faster growth.
Tactic for operators: If your platform's value to paying customers depends on who your users are — not just how many — invest in verification infrastructure before you invest in growth marketing. The verification moat compounds; the growth-hack moat doesn't.
Principle 2
Give away the complement to own the core.
Doximity's telehealth tools are free. Its e-fax service is free. Its news feed is free. Its credentialing tools are free. The company gives away an enormous amount of functionality — functionality that competitors charge for — because these features are not the product. They are the engagement engine that makes the product (pharmaceutical marketing access) valuable.
Free features that drive monetizable engagement
| Free Feature | Engagement Effect | Monetization Path |
|---|
| Telehealth (Dialer) | Daily platform usage; behavioral data | Enriched physician profiles for pharma targeting |
| E-fax | Referral network mapping; communication data | Referral pattern analytics sold to pharma |
| News feed | Session frequency; content engagement | Sponsored content and native pharma advertising |
| Credentialing | Verified identity; trust | EPCS compliance; premium trust signal for advertisers |
This is a classic complement-pricing strategy — the same logic that led Adobe to give away Acrobat Reader, or Google to give away Android. But in healthcare, it has a specific power: physicians are extraordinarily resistant to paying for professional tools out of pocket, and health systems are extraordinarily slow to procure new technology. By giving away the tools, Doximity bypasses both barriers simultaneously.
Benefit: Maximizes engagement and user penetration without requiring a consumer revenue model or enterprise sales cycle on the physician side.
Tradeoff: Structurally undermonetizes the user base. If a competitor offered comparable free tools with a better physician experience, Doximity's engagement moat could erode. The company is also forgoing potentially significant subscription revenue.
Tactic for operators: Identify what your paying customers are actually buying (in Doximity's case: verified physician attention) and give away everything that increases the supply of that asset, even if those giveaways look like standalone products.
Principle 3
Meet the market where it faxes.
Doximity did not try to convince physicians to abandon their existing workflows. It digitized those workflows. The e-fax service is the emblematic example: rather than insisting that physicians adopt a modern messaging protocol, Doximity built a bridge between the fax-based reality of American healthcare and the digital future it was constructing. The platform absorbed the fax, digitized it, extracted data from it, and made it searchable — all while the physician on the other end experienced nothing more jarring than a slightly better fax machine.
This principle — meeting your user at their current behavior rather than requiring them to adopt yours — is obvious in theory and almost universally violated in practice. The graveyard of healthcare technology is filled with companies that built beautiful, modern interfaces that required physicians to change how they practiced medicine. Physicians, as a rule, don't change how they practice medicine for a software company's convenience.
Benefit: Dramatically reduces adoption friction, which in a market with a finite number of users (there are only so many physicians) is the most critical variable. It also generates data from existing workflows that would otherwise be invisible.
Tradeoff: Meeting users where they are means building infrastructure for legacy systems — fax servers, pager integrations, compatibility with ancient EHR platforms — that is inglorious, technically complex, and never earns a feature article.
Tactic for operators: Before designing the ideal workflow, map the actual workflow your users follow today, including all its embarrassing, legacy components. Build your product to absorb that workflow, not replace it. The replacement comes later, once you've earned the trust and the data.
Principle 4
Build for the buyer, not the user — then make the user love you anyway.
Doximity's paying customers are pharmaceutical companies. Its users are physicians. The company must serve both, and the interests are not always aligned — physicians do not, in general, want to be marketed to, and pharmaceutical companies want, very much, to market to them. Doximity threads this needle by making the physician experience genuinely valuable independent of the advertising layer. The news feed, the telehealth tools, the credentialing services, the career resources — all of these serve the physician's interests directly. The pharmaceutical marketing is layered on top in the form of sponsored content that resembles, and often contains, clinically useful information.
This dual-audience problem is the defining challenge of any ad-supported platform, but in healthcare it is sharpened by regulatory constraints (HIPAA, PhRMA marketing codes, FDA promotional guidelines) and by the professional identity of the user. Physicians are trained skeptics. They evaluate evidence for a living. A platform that felt like a pharmaceutical marketing channel would lose physician trust instantly, and without physician trust, the platform has no value to sell.
Benefit: Creates a virtuous cycle where user love drives engagement, which drives advertiser value, which funds better user experiences. The alignment, when it works, is self-reinforcing.
Tradeoff: The tension is real. As Doximity scales its marketing solutions, the risk of crossing the line — of the platform feeling more like an advertising vehicle than a professional tool — increases. The equilibrium is fragile.
Tactic for operators: In two-sided markets, build the user-facing experience first and make it independently valuable. Only then layer in the monetization. If the user experience can't stand on its own without the paying customer, you have a media business, not a platform.
Principle 5
Stay small to stay fast.
Doximity generates more than $600,000 in revenue per employee — a figure that puts it in the top tier of software companies globally. This is not an accident of timing or the artifact of a high-margin business; it is the result of a deliberate organizational philosophy that treats headcount growth as a cost to be justified, not a metric to be optimized.
Tangney has explicitly stated that Doximity intends to stay lean indefinitely. The company has not made acquisitions. It has not built a large sales organization. It has not spun up a consulting practice or professional services arm. Each of these decisions forecloses a revenue opportunity in exchange for preserving the margin structure and organizational velocity that define the company.
Benefit: High margins, fast decision-making, strong per-share economics. The company can weather downturns without layoffs because it never over-hired during upturns.
Tradeoff: Limits the company's ability to pursue adjacent opportunities that require different capabilities. Doximity cannot easily build an EHR, enter clinical trials, or expand internationally — all of which would require fundamentally different talent and organizational scale.
Tactic for operators: Define the organizational constraint you're optimizing for — revenue per employee, speed to ship, margin structure — and make every hiring decision against that constraint. Growing headcount is the easiest thing in the world. Growing headcount without diluting organizational quality is among the hardest.
Principle 6
Let concentration be your moat, not your vulnerability.
Doximity's revenue concentration — top twenty customers representing 50–60% of revenue — is a risk factor that public market investors cite frequently. But concentration, in Doximity's specific context, also functions as a moat. The pharmaceutical industry is itself concentrated: the top twenty pharma companies account for a disproportionate share of global drug revenue and marketing spend. These are not customers that churn easily. They have multi-year marketing calendars, elaborate procurement processes, and a structural need to reach physicians through every available channel. Once embedded in a pharma company's marketing stack — with custom content modules, integrated analytics, and annual contracts — Doximity is difficult to displace.
The strategic imperative is not to reduce concentration (which would mean chasing smaller, less predictable accounts) but to deepen it: more products per customer, more use cases per product, higher switching costs per engagement. Doximity's expansion into interactive medical education, point-of-care messaging, and clinical workflow tools all serve this deepening strategy.
Benefit: Deep, high-value enterprise relationships with the largest spenders in healthcare marketing. Predictable revenue with high retention.
Tradeoff: A single customer's budget shift or a patent cliff at a major pharma company can materially affect quarterly revenue. The company is exposed to the drug-launch cycle in ways that pure SaaS businesses are not.
Tactic for operators: In markets with concentrated buyer power, don't diversify away from your best customers. Diversify within them. Build more products for the same buyers, increase your share of their budget, and make yourself indispensable to their workflow rather than a line item they review annually.
Principle 7
Compound per share, not per headline.
Since its IPO, Doximity has returned more than $1 billion to shareholders through stock buybacks — a remarkable capital allocation choice for a company that many analysts expected to pursue acquisitions. Tangney's logic is explicit: the highest-returning investment available to Doximity is Doximity. The business generates excess cash at a rate that exceeds any organic reinvestment opportunity, and the company's concentrated competitive position means that M&A would likely involve either overpaying for inferior assets or entering markets where it has no advantage.
The buyback strategy has meaningful implications for per-share economics. Even as revenue growth has decelerated from pandemic highs, earnings per share and free cash flow per share have continued to compound — because the denominator is shrinking. This creates a divergence between the "top-line growth" narrative (decelerating) and the "per-share value" narrative (compounding), and the market has not always recognized the distinction.
Benefit: Compounds per-share value without the integration risk, culture dilution, or strategic distraction of acquisitions. Sends a signal of capital discipline that attracts long-term shareholders.
Tradeoff: Forgoes optionality. If a transformative acquisition opportunity emerged — a physician engagement platform in Europe, a clinical data company, an EHR interoperability layer — Doximity would have to change its philosophy or watch a competitor seize the opportunity.
Tactic for operators: Before pursuing M&A, honestly assess whether your existing business can compound at a higher rate than any acquisition you're considering, after accounting for integration risk, culture dilution, and management distraction. The unsexy answer is often yes.
Principle 8
Own the vertical stack, not the horizontal layer.
The "LinkedIn for doctors" comparison flatters LinkedIn and obscures Doximity's actual strategy. LinkedIn is a horizontal platform — it does one thing (professional networking) across every industry. Doximity is a vertical platform — it does many things (networking, communication, telehealth, credentialing, education, career management, marketing) within one industry. The vertical approach allows Doximity to build features that reflect the specific regulatory, workflow, and professional norms of medicine in a way that no horizontal platform can.
This vertical depth is what makes the platform valuable to both sides of the market. Physicians use it because it understands their world. Pharma companies buy it because it reaches physicians in a professional context that general-purpose platforms cannot replicate. The depth of the vertical creates a feedback loop: more physician-specific features attract more physicians, which attracts more pharma spending, which funds more physician-specific features.
Benefit: Creates defensibility through domain-specific complexity that horizontal competitors cannot easily replicate. A new entrant would need to rebuild the verification infrastructure, the regulatory compliance layer, the clinical content curation, and the physician-specific workflows from scratch.
Tradeoff: The addressable market is bounded. There are roughly 1 million physicians in the U.S. and perhaps 2–3 million advanced practice providers. The total addressable physician marketing budget, while large, is not infinite. Vertical depth trades off against horizontal reach.
Tactic for operators: If you're building in a professional vertical, resist the temptation to abstract your platform horizontally before you've fully penetrated the vertical. The depth of your domain expertise is what makes you defensible. Once you go horizontal, you compete with generalists who have more resources.
Principle 9
Turn mundane data exhaust into strategic intelligence.
Every fax sent through Doximity is a data point about physician referral patterns. Every article read is a signal about clinical interest. Every telehealth call is a behavioral indicator. Every job listing viewed is career-intent data. The company's seemingly mundane features — fax, news, messaging — are, viewed through the lens of data strategy, a vast distributed sensor network measuring the professional behavior of 80% of American physicians in real time.
This data has compounding value. It trains the machine-learning models that power content recommendations and ad targeting. It informs the AI documentation tools the company is building. It creates the referral-network graphs that help pharmaceutical companies understand how prescribing decisions propagate through physician communities. And it generates the engagement metrics that justify the premium pricing Doximity commands for its marketing modules.
Benefit: Every product interaction generates data that improves every other product. This creates a flywheel effect where product usage compounds data quality, which compounds product value, which compounds usage.
Tradeoff: Data accumulation creates regulatory and reputational risk. Physician trust is the company's core asset, and any perception that Doximity is monetizing physician behavior inappropriately would be existential. The company must navigate HIPAA constraints, pharma marketing regulations, and the professional expectations of its user base with extreme care.
Tactic for operators: Design every feature, even the unglamorous ones, to generate data that feeds your core monetization engine. The most valuable data is often the exhaust of mundane, high-frequency behaviors — not the dramatic, low-frequency events.
Principle 10
Time your expansion to trust, not ambition.
Doximity has been conspicuously patient about expansion. The company has not entered international markets. It has not built a patient-facing product. It has not acquired an EHR company. It has not launched a clinical trials platform. Each of these opportunities has been discussed by analysts, and in each case Tangney has declined — not because the opportunities lack merit, but because the company's competitive advantage is trust, and trust is non-transferable across markets, user bases, and product categories.
The logic is disciplined: expand only into areas where your existing trust and data give you a structural advantage that newcomers cannot replicate. Doximity's AI documentation tools are a perfect example — they leverage the platform's existing data and physician relationships, and they serve the same user base that already trusts the platform. An international expansion, by contrast, would require rebuilding the verification infrastructure, the regulatory compliance layer, and the physician trust from scratch in every new market.
Benefit: Prevents the dilution of competitive advantage that comes from premature diversification. Each expansion is anchored in the existing moat rather than stretched beyond it.
Tradeoff: Patience can shade into complacency. If a competitor builds physician trust in an adjacent market — international, patient-facing, clinical workflow — and then expands back into Doximity's core, the company may find that its patience has allowed a flanking maneuver.
Tactic for operators: Before expanding into a new market or product area, ask: does our existing trust and data give us a structural advantage there, or would we be starting from scratch? If the answer is "starting from scratch," the expansion is likely a distraction, no matter how large the addressable market looks.
Conclusion
The Discipline of the Narrow Door
Doximity's playbook is, in essence, a playbook of disciplined narrowness. The company chose a specific audience (physicians), a specific buyer (pharmaceutical companies), a specific monetization model (marketing access), and a specific organizational philosophy (lean, profitable, patient) — and then executed on that narrow thesis with remarkable consistency for fifteen years. Every decision — the verification investment, the free telehealth tools, the buyback strategy, the refusal to acquire — flows from the same underlying conviction: that depth in a single vertical, compounded over time, creates more durable value than breadth across many.
This is not a universally applicable strategy. It works because the physician market has specific structural properties — a finite, identifiable user base with enormous economic influence, a concentrated buyer base with large budgets, and regulatory barriers that deter casual entry. But the meta-principle is transferable: in any market with these properties, the operator who goes deepest, earliest, and most patiently will likely win — and will likely be underestimated by observers who mistake narrowness for limitation.
The risk, always, is that the narrow door eventually becomes a box. Doximity's ceiling is set by the total amount of money pharmaceutical companies will spend marketing to physicians through digital channels. If that ceiling is $10 billion — a reasonable upper bound — the company has enormous room to grow. If it is $3 billion, the company is closer to saturation than its valuation implies. The answer, as with so many things in healthcare, will be determined by forces largely outside any single company's control: FDA approval cadences, patent cliff timing, reimbursement policy, and the glacial but inexorable digitization of an industry that still, in 2025, runs on fax machines.
Part IIIBusiness Breakdown
The Business at a Glance
Current Vital Signs
Doximity — FY2025
~$529MRevenue (FY2025 est.)
~53%Adjusted EBITDA margin
~37%Net income margin (FY2024)
$8B+Market capitalization (mid-2025)
~800Employees
80%+U.S. physicians on platform
110%+Net revenue retention rate
$1B+Cumulative share repurchases since IPO
Doximity occupies a peculiar position in the public market taxonomy. It is classified as a healthcare technology company but operates with the margin profile of an enterprise software business and the revenue model of a specialized media company. With roughly $529 million in estimated FY2025 revenue — growing in the low-to-mid teens percentage range — and adjusted EBITDA margins consistently above 50%, it is one of the most profitable companies of its size in the technology landscape. The business generates substantial free cash flow, carries minimal debt, and has used its cash position primarily for share repurchases rather than acquisitions or organic expansion into new markets.
The company's scale is best understood through two lenses. First, user penetration: more than 80% of U.S. physicians are on the platform, a market share number that would be extraordinary in any software category and is nearly unprecedented in healthcare technology. Second, monetization intensity: at roughly $250 in annual revenue per registered member (or approximately $1,000 per active user per year), the company is capturing only a small fraction of the total per-physician marketing spend — suggesting significant room for revenue expansion within the existing user base.
How Doximity Makes Money
Doximity's revenue is overwhelmingly concentrated in a single category — pharmaceutical and health system marketing — with smaller contributions from hiring solutions and emerging products.
FY2024 approximate composition
| Revenue Stream | Estimated Revenue | % of Total | Growth Trend |
|---|
| Marketing Solutions (Pharma & Health Systems) | ~$400M | ~85% | Growing |
| Hiring Solutions | ~$55M | ~12% | Stable |
| Other (Telehealth tools, emerging products) | ~$15M | ~3% | Early stage |
Marketing Solutions is the core business. Pharmaceutical companies, biotech firms, medical device manufacturers, and health systems purchase campaigns on the Doximity platform to reach verified physicians. The products include sponsored articles, interactive modules (branded medical education content), point-of-care messaging, and native content placements within the physician news feed. Pricing is based on reach (number of verified physicians exposed), engagement depth, and specialty targeting — campaigns targeting oncologists or cardiologists command higher CPMs than broad primary care campaigns.
The unit economics are exceptional. The platform's physician audience is a fixed asset — the members are already there, the verification is already done, the engagement tools are already built. The marginal cost of serving an additional sponsored article or interactive module is close to zero. This creates a revenue model with near-100% gross margins on incremental marketing spend, which is why adjusted EBITDA margins stay above 50% even after accounting for engineering, data science, and corporate overhead.
Hiring Solutions is Doximity's second revenue stream — a physician recruitment platform used by hospitals, medical groups, and staffing agencies. The product leverages Doximity's comprehensive physician database and career-intent signals (who is browsing job listings, who has updated their credentials, who is in a geography with physician surplus or shortage) to connect employers with candidates. Revenue comes from job listing fees and premium employer subscriptions.
Emerging Products — including AI documentation tools, analytics dashboards for pharma clients, and potential premium features — represent a small but strategically important category. The AI tools in particular could become a meaningful revenue driver if Doximity introduces premium subscriptions for physicians or enterprise licensing for health systems.
Competitive Position and Moat
Doximity's competitive position is defined by an unusual combination: near-monopoly user penetration in its core market, combined with a revenue model that has few direct competitors.
Five layers of competitive defense
| Moat Layer | Evidence | Durability |
|---|
| Verified physician network (80%+ penetration) | 2M+ verified members; DEA/NPI/license verification | Very High |
| Behavioral data asset | 15+ years of physician engagement, referral, and content data | High |
| Two-sided network effects | More physicians → more pharma spend → better tools → more physicians | High |
| Regulatory compliance (EPCS, HIPAA) | DEA-approved identity proofing; HIPAA-compliant messaging |
Direct competitors are few. No other platform has comparable physician penetration in the U.S. The closest analogs include:
-
Medscape (owned by WebMD Health / Internet Brands): A physician information and CME platform with significant physician engagement. Medscape competes for pharma marketing dollars and has a larger content operation. However, it lacks Doximity's verified identity layer, telehealth integration, and communication tools. The competitive dynamic is more complementary than zero-sum — pharma companies often buy campaigns on both platforms.
-
Epocrates (owned by athenahealth): Tangney's first company, still operational as a drug-reference tool. Narrow in scope and declining in strategic relevance.
-
LinkedIn (Microsoft): Horizontal professional network. Physicians use it, but it lacks healthcare-specific verification, HIPAA compliance, or clinical workflow tools. Not a meaningful competitor for pharma marketing budgets.
-
Sermo: A smaller physician social network (~800,000 global members) with a different monetization model focused on physician surveys and market research for pharma. Smaller scale, less engagement, less data depth.
-
EHR-embedded advertising platforms: Some electronic health record vendors (notably within the Epic ecosystem) have explored physician-facing content and messaging. This is a nascent but potentially significant competitive threat if EHR vendors decide to monetize physician attention within clinical workflows.
Where the moat is weakest: Doximity's moat is strongest on the supply side (physician penetration) and weakest on the demand side (pharma marketing budgets are discretionary and subject to reallocation). A new platform that offered pharmaceutical companies better targeting, better measurement, or better ROI attribution — even without Doximity's physician scale — could erode pricing power over time. The company also faces a ceiling risk: if 80% penetration is the maximum achievable (which it likely is, given that some physicians will never join any platform), growth must come from monetization intensity rather than user acquisition.
The Flywheel
Doximity's reinforcing cycle operates across both sides of its two-sided market, with data as the lubricant that accelerates each link.
How physician engagement compounds into competitive advantage
1. Physician utility → Engagement. Free, high-quality tools (telehealth, e-fax, credentialing, news, career resources) attract physicians and keep them returning to the platform daily. Each tool solves a real workflow problem, generating habitual usage.
2. Engagement → Data. Every interaction — article read, fax sent, telehealth call made, job listing viewed, message sent — generates behavioral data that enriches physician profiles and maps referral networks.
3. Data → Targeting precision. The accumulated data enables Doximity to offer pharmaceutical companies the most precise physician-targeting capabilities available on any digital platform. Campaigns can be targeted by specialty, prescribing behavior, geographic practice area, career stage, and clinical interests.
4. Targeting precision → Pharma revenue. Better targeting justifies premium pricing and drives pharmaceutical companies to increase their Doximity spend over time (reflected in 110%+ net revenue retention).
5. Pharma revenue → Platform investment. Revenue funds continued development of free physician tools, AI features, and data infrastructure — which loops back to Step 1.
6. Scale → Regulatory and data moat. At 80%+ physician penetration, the network itself becomes a regulatory-grade identity system (EPCS compliance) and a dataset that is impossible to replicate, raising barriers to entry for any competitor.
The flywheel's most important property is that it is self-reinforcing at the current scale. With 80%+ physician penetration already achieved, the network effects on the physician side are effectively locked in — the platform has the physicians, and physicians have no incentive to switch to a less comprehensive network. The growth vector is now almost entirely on the monetization axis: extracting more revenue per physician per year through expanded product offerings, deeper pharma engagement, and new revenue categories.
Growth Drivers and Strategic Outlook
Five specific vectors will determine Doximity's revenue trajectory over the next five to ten years.
1. Digital share of pharma marketing spend. The secular shift from in-person physician marketing (sales reps, conferences, dinner programs) to digital channels is the single most important macro driver. The total U.S. physician-directed marketing budget is approximately $30 billion. Digital currently represents an estimated 15–20% of that spend. If digital share reaches 40–50% over the next decade — consistent with the trajectory in other advertising verticals — the addressable digital market for physician-targeted marketing grows from roughly $5 billion to $12–15 billion. Doximity's ability to capture an increasing share of this expanding pool is the core growth thesis.
2. Revenue per physician expansion. At roughly $250 in annual revenue per registered member, Doximity is monetizing its audience at a fraction of the per-physician marketing spend. New product formats — interactive medical education modules, point-of-care messaging, AI-enhanced content personalization — can increase the number of marketing touchpoints per physician per year without requiring new physician acquisition.
3. AI-powered products. Clinical documentation tools, chart note summarization, prior authorization assistance, and patient communication drafting represent a potential new revenue category — either through premium physician subscriptions, enterprise licensing to health systems, or enhanced marketing analytics products for pharma clients. The TAM for AI-powered clinical workflow automation is estimated at $5–10 billion in the U.S. alone, though Doximity will address only the physician-facing, administrative segment.
4. Health system and employer expansion. Doximity's hiring solutions and health system marketing offerings represent a growing but still early revenue stream. As health systems face intensifying physician shortages — the Association of American Medical Colleges projects a shortage of up to 86,000 physicians by 2036 — the value of Doximity's physician career-intent data and recruitment tools increases.
5. International expansion. The company has no meaningful international presence today. The global physician population is approximately 12 million, suggesting a potential 5–6x expansion of the addressable user base. However, international expansion would require rebuilding verification infrastructure, navigating diverse regulatory environments, and competing with established local platforms in major markets. This remains a distant but potentially significant opportunity.
Key Risks and Debates
1. Pharma budget cyclicality and concentration. Doximity's top twenty customers represent 50–60% of revenue, and spending is correlated with drug-launch timing. Major patent cliffs — such as the loss of exclusivity for blockbuster drugs at AbbVie, Merck, and Bristol-Myers Squibb expected between 2025 and 2030 — could reduce marketing budgets at key customers precisely when Doximity needs them to grow. A single large customer pulling back 20–30% of their spend would be visible in quarterly results.
2. Revenue model fragility relative to SaaS. Doximity's marketing revenue is closer to an advertising business than a subscription business. While net revenue retention has been above 110%, the contracts are annual, the spend is discretionary, and pharma companies can reallocate budgets quarter to quarter. This makes the revenue less predictable than classic SaaS and more sensitive to macroeconomic and industry-specific cycles.
3. Platform competition from EHR vendors. Epic Systems, which dominates the U.S. EHR market, has explored physician-facing content and messaging within its clinical workflows. If Epic (or Cerner/Oracle) built a physician engagement layer inside the EHR — where physicians already spend most of their screen time — it could compete for physician attention in a way that a standalone platform like Doximity cannot easily match. This is the most structurally dangerous competitive threat because it would attack Doximity's engagement moat from inside the physician's primary workflow.
4. Regulatory and reputational risk. Doximity's business model involves collecting and monetizing physician behavioral data for pharmaceutical marketing purposes. While the company operates within HIPAA and FDA promotional guidelines, the political and regulatory environment around healthcare data, pharmaceutical marketing, and physician-industry relationships is volatile. A regulatory change — such as stricter limits on pharmaceutical marketing to physicians, or new data privacy requirements — could constrain the business model.
5. Growth ceiling in a finite market. With 80%+ of U.S. physicians already on the platform, Doximity cannot grow through user acquisition. Growth must come from monetization intensity — revenue per physician per year. If the digital pharma marketing market grows more slowly than expected, or if Doximity's product expansion fails to generate meaningful incremental revenue, the company could find itself at a growth ceiling that the current valuation does not reflect. At a market cap of $8+ billion — roughly 15–16x forward revenue — the stock prices in continued growth that is not guaranteed.
Why Doximity Matters
Doximity matters to operators and investors for reasons that extend well beyond the specifics of physician marketing.
It is, first, a proof of concept for the vertical platform thesis in professional services. The conventional wisdom in technology has long favored horizontal platforms — build for everyone, achieve scale, then monetize through advertising or subscriptions. Doximity demonstrates that a vertical platform, built with fanatical domain expertise and disciplined narrowness, can achieve horizontal-platform margins with vertical-platform defensibility. The lesson for founders building in legal, financial, engineering, or other professional verticals is that depth defeats breadth — if you pick the right audience and earn their trust.
It is, second, a case study in capital efficiency and owner-operator alignment. The company went public having already achieved profitability, has never made an acquisition, has returned over $1 billion to shareholders through buybacks, and employs fewer than 800 people. In an era of venture-subsidized growth, Doximity's financial discipline looks almost anachronistic — and its per-share economics, over the long term, may prove more durable than those of companies that grew faster but burned more capital in the process.
And it is, finally, a window into the strange, slow digitization of American healthcare — an industry that represents nearly 20% of U.S.
GDP, touches every human life, and still runs, in meaningful part, on fax machines. Doximity did not try to revolutionize this system. It inserted itself into the existing workflow, digitized the edges, earned the trust of the most powerful professionals in the system, and then monetized the attention it had earned. The strategy is patient, narrow, and — fifteen years in — still working. The fax machines are still humming. But the data center that receives them belongs to Doximity.
